Prio Wealth Limited Partnership Lowers Holdings in Danaher Co. (NYSE:DHR)

Prio Wealth Limited Partnership decreased its stake in Danaher Co. (NYSE:DHR) by 5.7% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 49,555 shares of the conglomerate’s stock after selling 2,985 shares during the quarter. Prio Wealth Limited Partnership’s holdings in Danaher were worth $12,381,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Oak Thistle LLC purchased a new position in shares of Danaher during the 2nd quarter valued at approximately $363,000. Caden Capital Partners LP boosted its stake in shares of Danaher by 12.4% during the 4th quarter. Caden Capital Partners LP now owns 139,068 shares of the conglomerate’s stock worth $32,172,000 after acquiring an additional 15,313 shares in the last quarter. HighPoint Advisor Group LLC acquired a new stake in shares of Danaher during the 4th quarter valued at about $2,614,000. Norden Group LLC purchased a new position in shares of Danaher in the 1st quarter valued at about $4,151,000. Finally, Duality Advisers LP acquired a new position in Danaher in the 1st quarter worth about $5,573,000. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Danaher

In other Danaher news, CEO Rainer Blair sold 9,007 shares of Danaher stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the completion of the sale, the chief executive officer now directly owns 97,983 shares in the company, valued at $27,435,240. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, CFO Matthew Mcgrew sold 16,172 shares of the firm’s stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $279.84, for a total value of $4,525,572.48. Following the completion of the transaction, the chief financial officer now owns 29,407 shares of the company’s stock, valued at $8,229,254.88. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Rainer Blair sold 9,007 shares of the company’s stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the sale, the chief executive officer now directly owns 97,983 shares in the company, valued at $27,435,240. The disclosure for this sale can be found here. Insiders have sold 39,659 shares of company stock valued at $11,042,433 over the last 90 days. 11.10% of the stock is owned by insiders.

Danaher Stock Performance

NYSE:DHR opened at $274.54 on Wednesday. The company’s 50-day moving average is $270.98 and its two-hundred day moving average is $258.24. The firm has a market capitalization of $203.35 billion, a price-to-earnings ratio of 46.53, a PEG ratio of 4.55 and a beta of 0.83. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04. Danaher Co. has a 1-year low of $182.09 and a 1-year high of $281.70.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, topping the consensus estimate of $1.57 by $0.15. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The company had revenue of $5.74 billion during the quarter, compared to analyst estimates of $5.59 billion. During the same period in the prior year, the business posted $2.05 earnings per share. The firm’s revenue for the quarter was down 2.9% compared to the same quarter last year. Analysts forecast that Danaher Co. will post 7.59 EPS for the current year.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Friday, September 27th will be issued a $0.27 dividend. The ex-dividend date of this dividend is Friday, September 27th. This represents a $1.08 annualized dividend and a yield of 0.39%. Danaher’s dividend payout ratio (DPR) is currently 18.31%.

Analysts Set New Price Targets

A number of research firms have recently commented on DHR. Stifel Nicolaus boosted their price objective on Danaher from $235.00 to $250.00 and gave the company a “hold” rating in a research report on Wednesday, July 24th. Barclays lifted their target price on shares of Danaher from $270.00 to $285.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 24th. StockNews.com downgraded shares of Danaher from a “buy” rating to a “hold” rating in a research report on Tuesday, June 25th. Evercore ISI lifted their price objective on Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a report on Tuesday. Finally, Wells Fargo & Company assumed coverage on Danaher in a report on Tuesday, August 27th. They set an “equal weight” rating and a $280.00 target price for the company. Seven investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $282.12.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.